WO2009062143A3 - Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor - Google Patents

Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor Download PDF

Info

Publication number
WO2009062143A3
WO2009062143A3 PCT/US2008/082967 US2008082967W WO2009062143A3 WO 2009062143 A3 WO2009062143 A3 WO 2009062143A3 US 2008082967 W US2008082967 W US 2008082967W WO 2009062143 A3 WO2009062143 A3 WO 2009062143A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
methods
growth factor
hepatocyte growth
regeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/082967
Other languages
French (fr)
Other versions
WO2009062143A2 (en
Inventor
Piero Anversa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Medical College
Original Assignee
New York Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Medical College filed Critical New York Medical College
Priority to AU2008323719A priority Critical patent/AU2008323719B2/en
Priority to EP08848337A priority patent/EP2219656A2/en
Priority to CA2743184A priority patent/CA2743184A1/en
Publication of WO2009062143A2 publication Critical patent/WO2009062143A2/en
Publication of WO2009062143A3 publication Critical patent/WO2009062143A3/en
Priority to IL205616A priority patent/IL205616A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for repairing damaged myocardium and/or myocardial cells including the administration of variants of hepatocyte growth factor or activated cardiac stem cells are disclosed and claimed. In addition, methods for forming coronary vasculature including the administration of variants of hepatocyte growth factor or activated cardiac stem cells are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed.
PCT/US2008/082967 2007-11-09 2008-11-10 Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof Ceased WO2009062143A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2008323719A AU2008323719B2 (en) 2007-11-09 2008-11-10 Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
EP08848337A EP2219656A2 (en) 2007-11-09 2008-11-10 Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
CA2743184A CA2743184A1 (en) 2007-11-09 2008-11-10 Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
IL205616A IL205616A (en) 2007-11-09 2010-05-09 Compositions containing hepatocyte growth factors for use in the repair or regeneration of damaged myocardium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98678807P 2007-11-09 2007-11-09
US60/986,788 2007-11-09

Publications (2)

Publication Number Publication Date
WO2009062143A2 WO2009062143A2 (en) 2009-05-14
WO2009062143A3 true WO2009062143A3 (en) 2010-01-07

Family

ID=40626468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/082967 Ceased WO2009062143A2 (en) 2007-11-09 2008-11-10 Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof

Country Status (6)

Country Link
US (2) US8247374B2 (en)
EP (1) EP2219656A2 (en)
AU (1) AU2008323719B2 (en)
CA (1) CA2743184A1 (en)
IL (1) IL205616A (en)
WO (1) WO2009062143A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846396B2 (en) 2003-07-31 2014-09-30 Universita Degli Studi Di Roma “La Sapienza” Methods for the isolation of cardiac stem cells

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110091428A1 (en) * 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
US7862810B2 (en) * 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP2245140A2 (en) * 2007-11-30 2010-11-03 New York Medical College Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
CA2743697A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2227238A2 (en) 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
AU2008334036B2 (en) 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
EP2303292A4 (en) 2008-06-09 2013-01-02 New York Medical College COMPOSITIONS COMPRISING CARDIAC STEM CELLS OVEREXPRESSING SPECIFIC MICROARNS AND METHODS OF USE THEREOF IN REPAIRING LASED MYOCARDIA
DK2498796T3 (en) 2009-11-09 2018-03-05 Aal Scient Inc HEART DISEASE TREATMENT
CN103037892A (en) * 2010-02-22 2013-04-10 布里格姆妇女医院 Compositions and methods for inducing angiogenesis
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US20140301989A1 (en) * 2011-06-17 2014-10-09 Brian Johnstone Methods for increasing the potency and efficacy of stem cells
WO2013037521A1 (en) * 2011-09-16 2013-03-21 Medical Research Council Modified hgf-1k1 polypeptide
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
WO2015081094A1 (en) 2013-11-27 2015-06-04 University Of Louisville Research Foundation, Inc. Cardiac progenitor cells and methods of use therefor
EP4494699A3 (en) 2014-10-03 2025-04-30 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
JP7336769B2 (en) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター Methods and compositions for treating skeletal muscular dystrophy
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND YRNA

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051798A1 (en) * 1997-05-10 1998-11-19 Imperial Cancer Research Technology Limited Hgf polypeptides and their use in therapy
WO2002002593A2 (en) * 2000-06-29 2002-01-10 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
WO2002088354A1 (en) * 2001-04-27 2002-11-07 Medical Research Council The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
US20030054973A1 (en) * 2001-06-06 2003-03-20 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US20050037431A1 (en) * 2003-06-06 2005-02-17 Genentech, Inc. Methods and compositions for modulating HGF/Met
WO2007058776A2 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
WO2007100530A2 (en) * 2006-02-16 2007-09-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
SE9100099D0 (en) 1991-01-11 1991-01-11 Kabi Pharmacia Ab USE OF GROWTH FACTOR
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5543318A (en) * 1991-06-12 1996-08-06 Smith; David A. Method of isolation, culture and proliferation of human atrial myocytes
EP0590066A4 (en) * 1991-06-12 1994-12-07 David A Smith Method for inducing human myocardial cell proliferation.
WO1995012979A1 (en) 1993-11-08 1995-05-18 The University Of Southern California Compositions and methods for transduction of cells
US5602301A (en) * 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US5610134A (en) 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US6174333B1 (en) * 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US5785966A (en) 1994-06-15 1998-07-28 Coles; John G. Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients
WO1996004314A1 (en) 1994-07-29 1996-02-15 Dade International, Inc. Mhc complexes and uses thereof
US5906934A (en) * 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US5712258A (en) * 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US5919449A (en) 1995-05-30 1999-07-06 Diacrin, Inc. Porcine cardiomyocytes and their use in treatment of insufficient cardiac function
US5908782A (en) * 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
CA2216439A1 (en) * 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6547787B1 (en) * 1997-03-13 2003-04-15 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
CA2218145C (en) * 1997-04-14 2008-01-08 Toshikazu Nakamura Method of treating dilated cardiomyopathy
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
US6110459A (en) * 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
US6387369B1 (en) * 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6001934A (en) * 1997-09-03 1999-12-14 Tonen Chemical Co. Process for the preparation of a functional group-containing polyarylene sulfide resin
JPH11246433A (en) 1998-03-03 1999-09-14 Sumitomo Pharmaceut Co Ltd Myocardial infarction treatment
WO1999045775A1 (en) 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
US20020122792A1 (en) * 1998-07-24 2002-09-05 Thomas J. Stegmann Induction of neoangiogenesis in ischemic myocardium
DE69937888T2 (en) 1998-07-31 2009-01-02 Genzyme Corp., Cambridge Process for the preparation of mesenchymal stem cells
CA2368677C (en) 1999-03-30 2012-07-10 Ran Kornowski Intramyocardial injection of autologous bone marrow
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
KR20010093804A (en) 1999-10-08 2001-10-29 무라야마 마사노리 Gene therapy for cardiomyopathy
US6329348B1 (en) 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
MXPA02012067A (en) 2000-06-05 2004-08-19 Univ Columbia Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury.
CA2505251A1 (en) * 2002-11-05 2004-05-27 Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
EP2245140A2 (en) * 2007-11-30 2010-11-03 New York Medical College Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
CA2743697A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
AU2008334036B2 (en) * 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
EP2227238A2 (en) * 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051798A1 (en) * 1997-05-10 1998-11-19 Imperial Cancer Research Technology Limited Hgf polypeptides and their use in therapy
WO2002002593A2 (en) * 2000-06-29 2002-01-10 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
WO2002088354A1 (en) * 2001-04-27 2002-11-07 Medical Research Council The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
US20030054973A1 (en) * 2001-06-06 2003-03-20 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US20050037431A1 (en) * 2003-06-06 2005-02-17 Genentech, Inc. Methods and compositions for modulating HGF/Met
WO2007058776A2 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
WO2007100530A2 (en) * 2006-02-16 2007-09-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LINKE AXEL ET AL: "Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 102, no. 25, 1 June 2005 (2005-06-01), pages 8966 - 8971, XP002520990, ISSN: 0027-8424 *
URBANEK KONRAD ET AL: "Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 97, no. 7, 1 September 2005 (2005-09-01), pages 663 - 673, XP002521032, ISSN: 0009-7330 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846396B2 (en) 2003-07-31 2014-09-30 Universita Degli Studi Di Roma “La Sapienza” Methods for the isolation of cardiac stem cells

Also Published As

Publication number Publication date
WO2009062143A2 (en) 2009-05-14
US8247374B2 (en) 2012-08-21
US8617889B2 (en) 2013-12-31
IL205616A0 (en) 2010-11-30
CA2743184A1 (en) 2009-05-14
US20090157046A1 (en) 2009-06-18
IL205616A (en) 2015-10-29
AU2008323719A1 (en) 2009-05-14
EP2219656A2 (en) 2010-08-25
AU2008323719B2 (en) 2013-04-04
US20130022584A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
WO2009062143A3 (en) Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
WO2007100530A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2010039823A3 (en) Compositions and methods for tissue repair with extracellular matrices
HK1212388A1 (en) Methods of tissue generation
NO20091133L (en) Use of 2-6- (3-amino-piperidin-L-yl) -3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
WO2010040129A3 (en) Scaffolds for tissue engineering and regenerative medicine
WO2009073616A3 (en) Compositions comprising vascular and myocyte progenitor cells and methods of their use
WO2007149861A3 (en) Soft tissue repair and regeneration using stem cell products
WO2009074807A3 (en) Methods
WO2007140964A3 (en) Scaffolds for artificial heart valves and vascular structures
WO2005113747A3 (en) Multicellular tissue and organ culture systems
WO2009079412A3 (en) Reverse transcriptase inhibitors
MX2010003217A (en) Angiogenic cells from human placental perfusate.
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
NO20081592L (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2009022133A3 (en) Scaffolds
MX341600B (en) Directional expansion of intraluminal devices.
WO2008051568A3 (en) Methods and compositions for treatment of bone defects with placental cell populations
WO2006068809A3 (en) Substrate recognition by differentiable human mesenchymal stem cells
DE602007011902D1 (en) SPIROINDOLINON DERIVATIVES
WO2001007568A3 (en) Muscle cells and their use in cardiac repair
WO2011057251A3 (en) Treatment of heart disease
PT2252321E (en) Composition comprising two or more isoforms of hepatocyte growth factor for use in treating incomplete revascularisation of the myocardium after coronary artery bypass grafting
UA113174C2 (en) FGF-18 STABLE LYOPHILIZED COMPOSITION
TN2009000362A1 (en) Weekly administration of dipeptidyl peptidase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848337

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 205616

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008848337

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008848337

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008323719

Country of ref document: AU

Date of ref document: 20081110

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2743184

Country of ref document: CA